F
Ferran Sanz
Researcher at Pompeu Fabra University
Publications - 227
Citations - 9540
Ferran Sanz is an academic researcher from Pompeu Fabra University. The author has contributed to research in topics: Health care & Health informatics. The author has an hindex of 40, co-authored 215 publications receiving 7054 citations. Previous affiliations of Ferran Sanz include Barcelona Biomedical Research Park & Autonomous University of Barcelona.
Papers
More filters
Journal ArticleDOI
DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants
Janet Piñero,Àlex Bravo,Núria Queralt-Rosinach,Alba Gutiérrez-Sacristán,Jordi Deu-Pons,Emilio Centeno,Javier Garcia-Garcia,Ferran Sanz,Laura I. Furlong +8 more
TL;DR: DisGeNET is a versatile platform that can be used for different research purposes including the investigation of the molecular underpinnings of specific human diseases and their comorbidities, the analysis of the properties of disease genes, the generation of hypothesis on drug therapeutic action and drug adverse effects, the validation of computationally predicted disease genes and the evaluation of text-mining methods performance.
Journal ArticleDOI
The DisGeNET knowledge platform for disease genomics: 2019 update.
Janet Piñero,Juan Manuel Ramírez-Anguita,Josep Saüch-Pitarch,Francesco Ronzano,Emilio Centeno,Ferran Sanz,Laura I. Furlong +6 more
TL;DR: The DisGeNET platform, a knowledge management platform integrating and standardizing data about disease associated genes and variants from multiple sources, is an interoperable resource supporting a variety of applications in genomic medicine and drug R&D.
Journal ArticleDOI
DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes
Janet Piñero,Núria Queralt-Rosinach,Àlex Bravo,Jordi Deu-Pons,Anna Bauer-Mehren,Martin Baron,Ferran Sanz,Laura I. Furlong +7 more
TL;DR: One of the most comprehensive collections of human gene-disease associations and a valuable set of tools for investigating the molecular mechanisms underlying diseases of genetic origin, designed to fulfill the needs of different user profiles, are offered.
Journal ArticleDOI
Adverse outcome pathways: opportunities, limitations and open questions.
Marcel Leist,Ahmed Ghallab,Ahmed Ghallab,Rabea Graepel,Rosemarie Marchan,Reham Hassan,Reham Hassan,Susanne Hougaard Bennekou,Alice Limonciel,Mathieu Vinken,Stefan Schildknecht,Tanja Waldmann,Erik H.J. Danen,Ben van Ravenzwaay,Hennicke Kamp,Iain Gardner,Patricio Godoy,Frédéric Y. Bois,Albert Braeuning,Raymond Reif,Franz Oesch,Dirk Drasdo,Dirk Drasdo,Stefan Höhme,Michael Schwarz,Thomas Hartung,Thomas Braunbeck,Joost B. Beltman,Harry Vrieling,Ferran Sanz,Anna Forsby,Anna Forsby,Domenico Gadaleta,Ciarán Fisher,Jens M. Kelm,David A. Fluri,Gerhard F. Ecker,Barbara Zdrazil,Andrea Terron,Paul Jennings,Bart van der Burg,Steven Dooley,Annemarie H. Meijer,Egon Willighagen,Egon Willighagen,Marvin Martens,Chris T. Evelo,Chris T. Evelo,Enrico Mombelli,Olivier Taboureau,Olivier Taboureau,Alberto Mantovani,Barry Hardy,Bjørn E. V. Koch,Sylvia Escher,Christoph van Thriel,Cristina Cadenas,Dinant Kroese,Bob van de Water,Jan G. Hengstler +59 more
TL;DR: The history of the AOP concept and its most prominent strengths are discussed, including the advantages of a formalized approach, the systematic collection of weight of evidence, the linkage of mechanisms to apical end points, the examination of the plausibility of epidemiological data, the identification of critical knowledge gaps and the design of mechanistic test methods.
Journal ArticleDOI
Pathway databases and tools for their exploitation: benefits, current limitations and challenges
TL;DR: Are the knowledge repositories of signalling pathways ready to realize the systems biology promise?